公开(公告)号：US20210214463A1

公开(公告)日：2021-07-15

申请号：US17212270

申请日：2021-03-25

Applicant: Silver Creek Pharmaceuticals, Inc.

Inventor： Ulrik Nielsen ,  Thomas Wickham ,  Birgit Schoeberl ,  Brian Harms ,  Bryan Linggi ,  Matthew Onsum ,  Byron DeLaBarre ,  Shaun M. Lippow

IPC: C07K16/44 ,  B82Y5/00 ,  C07K14/475 ,  C12N15/62 ,  A61K47/66 ,  A61K47/68 ,  A61K45/06 ,  C07K16/46 ,  C07K14/47 ,  C07K14/485 ,  C07K14/65

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

公开(公告)号：US11814443B2

公开(公告)日：2023-11-14

申请号：US17212270

申请日：2021-03-25

Applicant: Silver Creek Pharmaceuticals, Inc.

Inventor： Ulrik Nielsen ,  Thomas Wickham ,  Birgit Schoeberl ,  Brian Harms ,  Bryan Linggi ,  Matthew Onsum ,  Byron DeLaBarre ,  Shaun M. Lippow

IPC: A61K38/00 ,  A61K47/66 ,  A61K47/68 ,  C07K16/46 ,  B82Y5/00 ,  C07K14/475 ,  C12N15/62 ,  A61K45/06 ,  C07K14/47 ,  C07K14/485 ,  C07K14/65 ,  C07K16/44

CPC classification number: C07K16/46 ,  A61K45/06 ,  A61K47/66 ,  A61K47/6811 ,  A61K47/6891 ,  B82Y5/00 ,  C07K14/47 ,  C07K14/475 ,  C07K14/485 ,  C07K14/65 ,  C07K16/44 ,  C12N15/62 ,  A61K38/00 ,  C07K2317/31 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/80

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

公开(公告)号：US20210040233A1

公开(公告)日：2021-02-11

申请号：US17078978

申请日：2020-10-23

Applicant: Silver Creek Pharmaceuticals, Inc.

Inventor： Ulrik Bjerl Nielsen ,  Thomas Wickham ,  Birgit Schoeberl ,  Brian Harms ,  Bryan Linggi ,  Matthew Onsum ,  Byron DeLaBarre

IPC: C07K16/44 ,  B82Y5/00 ,  C07K14/475 ,  C12N15/62 ,  A61K47/66 ,  A61K47/68 ,  A61K45/06 ,  C07K16/46 ,  C07K14/47 ,  C07K14/485 ,  C07K14/65

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.

公开(公告)号：US20200048368A1

公开(公告)日：2020-02-13

申请号：US16524451

申请日：2019-07-29

Applicant: Silver Creek Pharmaceuticals, Inc.

Inventor： Ulrik Nielsen ,  Thomas Wickham ,  Birgit Schoeberl ,  Brian Harms ,  Bryan Linggi ,  Matthew Onsum ,  Byron DeLaBarre ,  Shaun M. Lippow

IPC: C07K16/44 ,  C07K14/65 ,  C07K14/485 ,  C07K14/47 ,  C07K16/46 ,  A61K45/06 ,  A61K47/68 ,  A61K47/66 ,  C12N15/62 ,  C07K14/475 ,  B82Y5/00

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

公开(公告)号：US11673970B2

公开(公告)日：2023-06-13

申请号：US17078978

申请日：2020-10-23

Applicant: Silver Creek Pharmaceuticals, Inc.

Inventor： Ulrik Bjerl Nielsen ,  Thomas Wickham ,  Birgit Schoeberl ,  Brian Harms ,  Bryan Linggi ,  Matthew Onsum ,  Byron DeLaBarre

IPC: B82Y5/00 ,  C07K14/475 ,  A61K47/66 ,  A61K47/68 ,  C07K16/46 ,  C07K14/47 ,  C07K14/65 ,  A61K38/00 ,  C07K16/44 ,  C12N15/62 ,  A61K45/06 ,  C07K14/485

CPC classification number: C07K16/46 ,  A61K45/06 ,  A61K47/66 ,  A61K47/6811 ,  A61K47/6891 ,  B82Y5/00 ,  C07K14/47 ,  C07K14/475 ,  C07K14/485 ,  C07K14/65 ,  C07K16/44 ,  C12N15/62 ,  A61K38/00 ,  C07K2317/31 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/80

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.

公开(公告)号：US10988547B2

公开(公告)日：2021-04-27

申请号：US16524451

申请日：2019-07-29

Applicant: Silver Creek Pharmaceuticals, Inc.

Inventor： Ulrik Nielsen ,  Thomas Wickham ,  Birgit Schoeberl ,  Brian Harms ,  Bryan Linggi ,  Matthew Onsum ,  Byron DeLaBarre ,  Shaun M. Lippow

IPC: C07K14/475 ,  C07K16/44 ,  B82Y5/00 ,  C12N15/62 ,  A61K47/66 ,  A61K47/68 ,  A61K45/06 ,  C07K16/46 ,  C07K14/47 ,  C07K14/485 ,  C07K14/65 ,  A61K38/00

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

公开(公告)号：US10858450B2

公开(公告)日：2020-12-08

申请号：US15957252

申请日：2018-04-19

Applicant: Silver Creek Pharmaceuticals, Inc.

Inventor： Ulrik Bjerl Nielsen ,  Thomas Wickham ,  Birgit Schoeberl ,  Brian Harms ,  Bryan Linggi ,  Matthew Onsum ,  Byron DeLaBarre

IPC: C07K16/44 ,  B82Y5/00 ,  A61K47/66 ,  A61K47/68 ,  C07K16/46 ,  C07K14/47 ,  A61K38/00 ,  C07K14/475 ,  C12N15/62 ,  A61K45/06 ,  C07K14/485 ,  C07K14/65

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.

公开(公告)号：US20240101713A1

公开(公告)日：2024-03-28

申请号：US18483308

申请日：2023-10-09

Applicant: Silver Creek Pharmaceuticals, Inc.

Inventor： Ulrik Nielsen ,  Thomas Wickham ,  Birgit Schoeberl ,  Brian Harms ,  Bryan Linggi ,  Matthew Onsum ,  Byron DeLaBarre ,  Shaun M. Lippow

IPC: C07K16/46 ,  A61K45/06 ,  A61K47/66 ,  A61K47/68 ,  B82Y5/00 ,  C07K14/47 ,  C07K14/475 ,  C07K14/485 ,  C07K14/65 ,  C07K16/44 ,  C12N15/62

CPC classification number: C07K16/46 ,  A61K45/06 ,  A61K47/66 ,  A61K47/6811 ,  A61K47/6891 ,  B82Y5/00 ,  C07K14/47 ,  C07K14/475 ,  C07K14/485 ,  C07K14/65 ,  C07K16/44 ,  C12N15/62 ,  A61K38/00 ,  C07K2319/00

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

公开(公告)号：US20230322951A1

公开(公告)日：2023-10-12

申请号：US18311306

申请日：2023-05-03

Applicant: Silver Creek Pharmaceuticals, Inc.

Inventor： Ulrik Bjerl Nielsen ,  Thomas Wickham ,  Birgit Schoeberl ,  Brian Harms ,  Bryan Linggi ,  Matthew Onsum ,  Byron DeLaBarre

IPC: C07K16/46 ,  B82Y5/00 ,  C07K14/475 ,  C12N15/62 ,  A61K47/66 ,  A61K47/68 ,  A61K45/06 ,  C07K14/47 ,  C07K14/485 ,  C07K14/65 ,  C07K16/44

CPC classification number: C07K16/46 ,  B82Y5/00 ,  C07K14/475 ,  C12N15/62 ,  A61K47/66 ,  A61K47/6811 ,  A61K47/6891 ,  A61K45/06 ,  C07K14/47 ,  C07K14/485 ,  C07K14/65 ,  C07K16/44 ,  C07K2319/00 ,  A61K38/00

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.

公开(公告)号：US10407512B2

公开(公告)日：2019-09-10

申请号：US15618478

申请日：2017-06-09

Applicant: Silver Creek Pharmaceuticals, Inc.

Inventor： Ulrik Nielsen ,  Thomas Wickham ,  Birgit Schoeberl ,  Brian Harms ,  Bryan Linggi ,  Matthew Onsum ,  Byron DeLaBarre ,  Shaun M. Lippow

IPC: C07K14/475 ,  C07K16/44 ,  B82Y5/00 ,  C12N15/62 ,  A61K45/06 ,  C07K16/46 ,  C07K14/47 ,  C07K14/485 ,  C07K14/65 ,  A61K47/66 ,  A61K47/68 ,  A61K38/00

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.